Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) – Part I: In Vitro Testing and Characterization
A high-efficiency aerosol SLS product was designed and tested that may enable an order of magnitude reduction in administered phospholipid dose, and provide rapid aerosol administration to infants with RDS.
Authors
- Dale Farkas (ORCID: https://orcid.org/0000-0001-7295-7555)
- Michael Hindle (ORCID: https://orcid.org/0000-0002-1025-1183)
- P. Worth Longest (ORCID: https://orcid.org/0000-0003-4939-5691)
- Felicia Hall
- Mohammad A. M. Momin (ORCID: https://orcid.org/0000-0003-1463-0719)
- Robert M DiBlasi (ORCID: https://orcid.org/0000-0002-9206-7346)
Institutions
- Seattle Children's Hospital (US)
- Virginia Commonwealth University (US)
Publication Details
- Journal
- Pharmaceutical Research
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1007/s11095-024-03740-z
- Citations
- 7
- Primary Topic
- Neonatal Respiratory Health Research
- Type
- article
- Field-Weighted Citation Impact
- 2.93
Funders
- Bill and Melinda Gates Foundation
- National Institutes of Health
- University of California, Irvine
- National Heart, Lung, and Blood Institute